Schizophrenia Trial, Recruiting NCT06045897 Sponsor: Centre Hospitalier St Anne Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT06045897
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 15 and 30 years
  • People who meet a specific set of clinical criteria (called CAARMS criteria) for an "at-risk mental state," meaning they have mild to moderate early warning signs that may or may not develop into a more serious condition — there are two levels: Stage Ia (mild or vague symptoms and mild difficulties with daily functioning) and Stage Ib (moderate symptoms that are not yet at a level requiring intervention, and moderate difficulties with daily functioning)
  • People who have recently experienced their first episode of psychotic symptoms, as identified using standard diagnostic guidelines (DSM-5)
  • People who meet the standard diagnostic criteria (DSM-5) for a depressive disorder
  • People who meet the standard diagnostic criteria (DSM-5) for autism spectrum disorder
  • Healthy volunteers from the general public who do not have any of the conditions listed above

Who may not be able to join:

  • People who are considered to be at risk of suicide
  • People with serious or unstable physical health or neurological conditions
  • People who have epilepsy
  • People who have had a significant head injury
  • People whose assessed IQ is below 70
  • Healthy volunteers who have a family history of psychosis
  • People who have been diagnosed with bipolar disorder
  • People who have been diagnosed with obsessive-compulsive disorder
  • People with a substance use disorder — note that cannabis use of up to 5 joints per day may be tolerated (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Anton Iftimovici, MD, PhD, GHU Paris Psychiatrie et Neurosciences

Phone: 0033(0)145658179

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier St Anne
Registry
ClinicalTrials.gov
Start date
30 May 2023
Est. completion
30 July 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Occurrence of EEG microstates; Coverage of EEG microstates; Mean duration of EEG microstates

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov